{"id":"oral-pf-07220060","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"Strong CYP3A inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"Strong CYP3A inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2C8 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2C8 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP3A substrates","action":"Monitor","effect":"Increased exposure to CYP3A substrates"},{"drug":"CYP2C8 substrates","action":"Monitor","effect":"Increased exposure to CYP2C8 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"}],"commonSideEffects":[],"contraindications":["No contraindications mentioned in the text."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"No information available","Renal impairment":"No information available","Hepatic impairment":"No information available"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=oral-pf-07220060","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:48.588347+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:51:04.365846+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:53.978650+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:48.662158+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=oral-pf-07220060","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:54.302625+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108778/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:55.465850+00:00"}},"allNames":"oral pf-07220060","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Oral PF-07220060, marketed by Pfizer, is positioned in the multiple myeloma segment, a critical area in oncology. The drug's key patent expires in 2028, providing a period of market exclusivity. However, it faces significant competition from other CDK4/6 inhibitors such as Palbociclib, Ribociclib, and Abemaciclib, which are established in treating HR+/HER2- mBC patients.","brandName":"Oral PF-07220060","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for PF-07220060 is not specified, making it difficult for healthcare professionals to understand its pharmacological effects. Further studies are required to elucidate the drug's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:38.655Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=oral-pf-07220060","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=oral-pf-07220060","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:51:04.365939+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Palbociclib","company":"Pfizer","advantage":"Palbociclib is a CDK4/6 inhibitor that competes with PF-07220060 in treating HR+/HER2- mBC patients."},{"name":"Ribociclib","company":"Novartis","advantage":"Ribociclib is a CDK4/6 inhibitor that competes with PF-07220060 in treating HR+/HER2- mBC patients."},{"name":"Abemaciclib","company":"Eli Lilly and Company","advantage":"Abemaciclib is a CDK4/6 inhibitor that competes with PF-07220060 in treating HR+/HER2- mBC patients."}],"genericName":"oral-pf-07220060","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"},{"name":"Relapsed or Refractory Multiple Myeloma","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06267963","phase":"PHASE1","title":"A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT06206837","phase":"PHASE1, PHASE2","title":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-02-19","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT07130097","phase":"PHASE1","title":"A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-08-14","conditions":"Healthy Participant","enrollment":35},{"nctId":"NCT07160738","phase":"PHASE1","title":"A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-22","conditions":"Healthy Adults","enrollment":28},{"nctId":"NCT06465368","phase":"PHASE2","title":"A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-11","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT05216432","phase":"PHASE1","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2021-12-08","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":930},{"nctId":"NCT05262400","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-14","conditions":"Breast Cancer, Solid Tumors","enrollment":192},{"nctId":"NCT05923411","phase":"PHASE1","title":"A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-11","conditions":"Healthy Participants","enrollment":113}],"_emaApprovals":[{"date":"","name":"Oral PF-07220060","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component","molecularWeight":""},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108778"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:51:04.365939+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}